^
Association details:
Biomarker:PD-L2 deletion
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Genomic correlates of PD-L1 expression are associated with response to immunotherapy in non-small cell lung cancer

Published date:
04/28/2020
Excerpt:
STK11 mutation (Log-rank test, q=0.1), EGFR mutation (q<1e-3), and CN loss of PD-L1, PD-L2, and/or JAK2 (q=0.02) were all significantly associated with worse PFS after ICB. EGFR mutation was significantly associated with worse OS after ICB (q=0.19).